Schwab Charles Investment Management Inc. lifted its holdings in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 50.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 242,934 shares of the biotechnology company’s stock after purchasing an additional 81,735 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.38% of Heron Therapeutics worth $4,398,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in HRTX. Trexquant Investment LP acquired a new stake in shares of Heron Therapeutics during the third quarter worth about $206,000. Jane Street Group LLC acquired a new stake in shares of Heron Therapeutics during the third quarter worth about $223,000. Parametric Portfolio Associates LLC raised its position in shares of Heron Therapeutics by 2.3% during the second quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 771 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Heron Therapeutics by 30.6% during the second quarter. The Manufacturers Life Insurance Company now owns 34,741 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 8,135 shares during the period. Finally, Royce & Associates LP raised its position in shares of Heron Therapeutics by 17.4% during the third quarter. Royce & Associates LP now owns 67,500 shares of the biotechnology company’s stock worth $1,090,000 after purchasing an additional 10,000 shares during the period.
HRTX stock opened at $28.20 on Friday. Heron Therapeutics Inc has a fifty-two week low of $12.70 and a fifty-two week high of $32.70.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.29). The firm had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9.00 million. Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. equities research analysts predict that Heron Therapeutics Inc will post -2.53 EPS for the current year.
A number of research firms have recently commented on HRTX. BidaskClub raised Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, February 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target (up previously from $28.00) on shares of Heron Therapeutics in a research report on Thursday, March 1st. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Oppenheimer set a $34.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 19th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $33.00.
In other Heron Therapeutics news, CEO Barry D. Quart sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $29.75, for a total value of $2,975,000.00. Following the completion of the transaction, the chief executive officer now directly owns 167,993 shares in the company, valued at $4,997,791.75. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Kimberly Manhard sold 18,000 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $30.00, for a total value of $540,000.00. Following the completion of the transaction, the vice president now owns 18,000 shares of the company’s stock, valued at $540,000. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 225,584 shares of company stock valued at $6,141,680. Corporate insiders own 19.93% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Heron Therapeutics Inc (NASDAQ:HRTX) Stake Increased by Schwab Charles Investment Management Inc.” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/24/schwab-charles-investment-management-inc-has-4-40-million-stake-in-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.